Joint pain
An area of high clinical demand. With real room for differentiation.
The viscosupplementation and intra-articular support market is one of the most active segments in medical device distribution.
Demand is constant, driven by an ageing population and a growing focus on conservative orthopaedic medicine. But it is also a market where the commodity reigns: products with similar formulations, indistinct positioning, price wars.
For the distributor looking to build a recognisable presence in this segment, formulation differentiation is not an aesthetic detail: it is the primary lever to justify positioning, sustain margins and build loyalty in the clinical channel.
Five products, one rationale: covering the market without overlapping
The Alfakjn joint pain range is designed to offer the distributor complete coverage of the segment without the products cannibalising each other:
- A classic intra-articular injection using Joyflex 1.6%, designed for professionals and markets already familiar with standard viscosupplementation
- The Joyflex 2% solution offers a higher dosage whilst maintaining the same treatment regimen as conventional viscosupplementation.
- A simplified proposal with Joyflex One, for contexts where single-dose or protocol convenience are primary values.
- A superior and patented positioning with Joyflex Proakjn® and Joyflex Proakjn® XL, for markets ready to consider integrated regenerative approaches.
This structure allows the distributor to tailor an offering by market level and clinical channel maturity, without having to source complementary products from other suppliers.
The Alfakjn range for joint pain
Joyflex 1.6%
Hyaluronic acid solution 16 mg/ml for intra-articular injection.
Standard formulation with a well-established clinical profile and comprehensive technical documentation.
Suitable for gonarthrosis and arthritic conditions in the symptomatic phase.
For the distributor: entry-level product for the segment, with a broad clinical reference base and a clear positioning in the orthopaedic and physical medicine channel.
Joyflex 1.6%
Hyaluronic acid solution 16 mg/ml for intra-articular injection.
Standard formulation with a well-established clinical profile and comprehensive technical documentation.
Suitable for gonarthrosis and arthritic conditions in the symptomatic phase.
For the distributor: entry-level product for the segment, with a broad clinical reference base and a clear positioning in the orthopaedic and physical medicine channel.
Joyflex® 2%
Hyaluronic acid solution for intra-articular injection.
High-dose 20 mg/ml formulation with an established clinical profile and comprehensive technical documentation.
Suitable for gonarthrosis and arthritic conditions in the symptomatic phase.
For the distributor: evolution of the standard formulation, with a broad clinical reference base and a clear positioning in the orthopaedic and physiatric channel.
Joyflex® 2%
Hyaluronic acid solution for intra-articular injection.
High-dose 20 mg/ml formulation with an established clinical profile and comprehensive technical documentation.
Suitable for gonarthrosis and arthritic conditions in the symptomatic phase.
For the distributor: evolution of the standard formulation, with a broad clinical reference base and a clear positioning in the orthopaedic and physiatric channel.
Joyflex® One
Single-dose formulation for intra-articular injection.
It responds to the growing preference for simplified, single-use protocols in high-volume clinical settings.
For the distributor: accessible proposal that broadens the prescribing base without displacing the premium positioning of the Proakjn line.
Joyflex® One
Single-dose formulation for intra-articular injection.
It responds to the growing preference for simplified, single-use protocols in high-volume clinical settings.
For the distributor: accessible proposal that broadens the prescribing base without displacing the premium positioning of the Proakjn line.
Joyflex Proakjn®
Patented medical device that integrates viscosupplementation and prolotherapy into a single formulation.
The active patent covers the combination of the two therapeutic actions, positioning the product exclusively in the advanced intra-articular market.
For the distributor: the primary differentiator. It enables the creation of a clinical narrative that stands out from competitors, with a verifiable intellectual property proof point.
Joyflex Proakjn®
Patented medical device that integrates viscosupplementation and prolotherapy into a single formulation.
The active patent covers the combination of the two therapeutic actions, positioning the product exclusively in the advanced intra-articular market.
For the distributor: the primary differentiator. It enables the creation of a clinical narrative that stands out from competitors, with a verifiable intellectual property proof point.
Joyflex Proakjn® XL
Patented medical device that integrates viscosupplementation and prolotherapy in a larger volume syringe.
The active patent covers the combination of the two therapeutic actions, positioning the product exclusively in the advanced intra-articular market.
For the distributor: the core differentiating product. It allows you to build a clinical narrative that stands out from competitors, in a higher-dose version.
Joyflex Proakjn® XL
Patented medical device that integrates viscosupplementation and prolotherapy in a larger volume syringe.
The active patent covers the combination of the two therapeutic actions, positioning the product exclusively in the advanced intra-articular market.
For the distributor: the core differentiating product. It allows you to build a clinical narrative that stands out from competitors, in a higher-dose version.What does the partnership include for this area
Alfakjn provides its distribution partners, for the joint pain line, with:
- Comprehensive technical and clinical documentation (in accordance with current European regulations, in English)
- Presentation materials for the healthcare professional, adaptable for market
- Support with product positioning against local competitors
- Willingness to consider local brand names, subject to regulatory compliance
